Title,Authors,Platform,Cited_url,Cited_count,Year
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis,CAMMS223 Trial Investigators,"New England Journal of Medicine 359 (17), 1786-1801",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4510324967252921803,917,2008
McAlpine's multiple sclerosis,"D McAlpine, A Compston",Elsevier Health Sciences,"https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6631532181510443557,7252654487084765192,7187990578619719736,7544066566568337382,15944102709599023789",808,2005
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial,"JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...","The Lancet 380 (9856), 1819-1828",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1099852625643761166,775,2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial,"AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...","The lancet 380 (9856), 1829-1839",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6610950806618990191,773,2012
Multiple sclerosis,"A Compston, A Coles","Lancet (British edition) 372 (9648), 1502-1517",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8288463776492059813,697,2008
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis,"AJ Coles, MG Wing, P Molyneux, A Paolillo, CM Davie, G Hale, D Miller, ...",Annals of Neurology: Official Journal of the American Neurological …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13071335826584810102,545,1999
The window of therapeutic opportunity in multiple sclerosis,"AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ...","Journal of neurology 253 (1), 98-108",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7000448304424781052,483,2006
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis,"AJ Coles, M Wing, S Smith, F Coraddu, S Greer, C Taylor, A Weetman, ...","The Lancet 354 (9191), 1691-1695",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7277702215067451256,458,1999
Multiple sclerosis,"A Compston, A Coles","Lancet (British edition) 359 (9313), 1221-1231",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11066766100170626759,284,2002
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis,"T Moreau, A Coles, M Wing, J Isaacs, G Hale, H Waldmann, A Compston","Brain 119 (1), 225-237",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18394739940579351836,280,1996
Disease-relevant autoantibodies in first episode schizophrenia,"MS Zandi, SR Irani, B Lang, P Waters, PB Jones, P McKenna, AJ Coles, ...","Journal of neurology 258 (4), 686-688",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8661290300049531213,278,2011
"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","JL Jones, CL Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, ...","The Journal of clinical investigation 119 (7), 2052-2061",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1115104335218611022,259,2009
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis,"AL Cox, SAJ Thompson, JL Jones, VH Robertson, G Hale, H Waldmann, ...","European journal of immunology 35 (11), 3332-3342",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11153224000593824678,248,2005
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial,"AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, A Skoromets, ...","Neurology 78 (14), 1069-1078",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11521751774102723662,233,2012
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H,"A Paolillo, AJ Coles, PD Molyneux, M Gawne–Cain, D MacManus, ...","Neurology 53 (4), 751-751",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7358749610241799683,230,1999
Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans,"E Schoenmakers, M Agostini, C Mitchell, N Schoenmakers, L Papp, ...","The Journal of clinical investigation 120 (12), 4220-4235",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4769484519678385673,212,2010
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort,"M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ...","Neurology 77 (6), 573-579",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3509198145168986227,186,2011
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy,"O Tuohy, L Costelloe, G Hill-Cawthorne, I Bjornson, K Harding, ...","J Neurol Neurosurg Psychiatry 86 (2), 208-215",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2895010708538451306,167,2015
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis,"SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles","Journal of clinical immunology 30 (1), 99-105",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9806310498133354942,166,2010
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity,"JL Jones, JM Anderson, CL Phuah, EJ Fox, K Selmaj, D Margolin, ...","Brain 133 (8), 2232-2247",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5280339358473125978,160,2010
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis,"GA Hill-Cawthorne, T Button, O Tuohy, JL Jones, K May, J Somerfield, ...","J Neurol Neurosurg Psychiatry 83 (3), 298-304",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10006960546682338337,142,2012
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes,"AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, ...","The Lancet Neurology 10 (4), 338-348",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15714509618192109085,142,2011
CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 …,"JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...","Lancet 380 (9856), 1819-1828",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7401990159182564249,141,2012
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation,"JL Jones, SAJ Thompson, P Loh, JL Davies, OC Tuohy, AJ Curry, ...","Proceedings of the National Academy of Sciences 110 (50), 20200-20205",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1647101853546069039,127,2013
Distribution of multiple sclerosis,"A Compston, A Coles",,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11857848138674250098,123,1998
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple …,"SV Abrahamsson, DF Angelini, AN Dubinsky, E Morel, U Oh, JL Jones, ...","Brain 136 (9), 2888-2903",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15779520329131869864,122,2013
CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial,"AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...","Lancet 380 (9856), 1829-1839",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15479536445578035767,117,2012
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis,"N Scolding, D Barnes, S Cader, J Chataway, A Chaudhuri, A Coles, ...","Practical neurology 15 (4), 273-279",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13119480700587865319,115,2015
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings,"AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...","Neurology 89 (11), 1117-1126",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12862746373297642504,98,2017
Antibody-mediated encephalitis: a treatable cause of schizophrenia,"BR Lennox, AJ Coles, A Vincent","The British Journal of Psychiatry 200 (2), 92-94",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13537594781063514869,96,2012
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench,"A Coles, J Deans, A Compston","Clinical neurology and neurosurgery 3 (106), 270-274",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15369983065096323506,95,2004
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis,"A Cuker, AJ Coles, H Sullivan, E Fox, M Goldberg, P Oyuela, A Purvis, ...","Blood 118 (24), 6299-6305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15578478922153556619,88,2011
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy,"E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...","Neurology 89 (11), 1107-1116",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3155385441487863673,81,2017
"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...","The Lancet Neurology 16 (4), 271-281","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13708433942025584274,9550061390287300633",80,2017
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy,"EA Marsh, CL Hirst, JG Llewelyn, MD Cossburn, MM Reilly, A Krishnan, ...","Journal of neurology 257 (6), 913-919",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16316224066364545984,79,2010
Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes,"MS Zandi, RW Paterson, MA Ellul, L Jacobson, A Al-Diwani, JL Jones, ...","J Neurol Neurosurg Psychiatry 86 (7), 708-713",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1460477258308281316,77,2015
Decreased iNOS synthesis mediates dexamethasone‐induced protection of neurons from inflammatory injury ,"S Golde, A Coles, JA Lindquist, A Compston","European Journal of Neuroscience 18 (9), 2527-2537",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7503511243304491918,75,2003
CAMPATH-1H in multiple sclerosis,"T Moreau, A Coles, M Wing, J Thorpe, D Miller, I Moseley, J Issacs, ...","Multiple Sclerosis Journal 1 (6), 357-365",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14030828142956340991,73,1996
Alemtuzumab therapy for multiple sclerosis,AJ Coles,"Neurotherapeutics 10 (1), 29-33",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1686299279991755022,69,2013
Inflammatory events at blood–brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease,"HE de Vries, G Kooij, D Frenkel, S Georgopoulos, A Monsonego, ...","Epilepsia 53, 45-52",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4839063222738398312,68,2012
MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences,"ML Gawne-Cain, JI O’Riordan, A Coles, B Newell, AJ Thompson, ...","Journal of Neurology, Neurosurgery & Psychiatry 64 (2), 197-203",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3917402934189191141,66,1998
Lower extremity motor evoked potentials in multiple sclerosis,"SM Jones, LJ Streletz, VE Raab, RL Knobler, FD Lublin","Archives of neurology 48 (9), 944-948",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10438836211910506217,63,1991
Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy,"KAC Harkness, A Coles, U Pohl, JH Xuereb, JC Baron, GG Lennox","European journal of neurology 11 (1), 59-62",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7726515871237618551,60,2004
A novel strategy to reduce the immunogenicity of biological therapies,"J Somerfield, GA Hill-Cawthorne, A Lin, MS Zandi, C McCarthy, JL Jones, ...","The Journal of Immunology 185 (1), 763-768",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11386679185428558994,53,2010
Immune competence after alemtuzumab treatment of multiple sclerosis,"CL McCarthy, O Tuohy, DAS Compston, DS Kumararatne, AJ Coles, ...","Neurology 81 (10), 872-876",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5765651187113415215,52,2013
Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.,"N Tubridy, AJ Coles, P Molyneux, DA Compston, F Barkhof, AJ Thompson, ...","Brain: a journal of neurology 121 (2), 225-231",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2484784518502378183,52,1998
Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.,"MS Zandi, JB Deakin, K Morris, C Buckley, L Jacobson, L Scoriels, ...","Schizophrenia research 160 (1-3), 193",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9460344355759245491,51,2014
Campath-1H treatment of multiple sclerosis,"JL Jones, AJ Coles","Neurodegenerative Diseases 5 (1), 27-31",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15268669240285905497,46,2008
Mode of action and clinical studies with alemtuzumab,"JL Jones, AJ Coles","Experimental neurology 262, 37-43",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13460892909204888017,45,2014
New treatment strategies in multiple sclerosis,"JL Jones, AJ Coles","Experimental neurology 225 (1), 34-39",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7833915338962425521,45,2010
Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4,"AJ Coles, S Thompson, AL Cox, S Curran, EM Gurnell, VK Chatterjee","European journal of immunology 35 (12), 3694-3703",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7496920007443169512,43,2005
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity,"O Kousin-Ezewu, L Azzopardi, RA Parker, O Tuohy, A Compston, A Coles, ...","Neurology 82 (24), 2158-2164",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8215386700823561869,41,2014
An investigation of auto-reactivity after head injury,"AL Cox, AJ Coles, J Nortje, PG Bradley, DA Chatfield, SJ Thompson, ...","Journal of neuroimmunology 174 (1-2), 180-186",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8221919878778927846,41,2006
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis,"JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...","Jama 321 (2), 175-187",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8315017498184434946,40,2019
‘Radiologically compatible CLIPPERS’may conceal a number of pathologies,"JL Jones, AF Dean, N Antoun, DJ Scoffings, NG Burnet, AJ Coles","Brain 134 (8), e187-e187",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7704894212238140335,38,2011
Spotlight on alemtuzumab,"JL Jones, AJ Coles","Int MS J 16 (3), 77-81",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5554202287617920007,38,2009
Alemtuzumab treatment of multiple sclerosis,AJ Coles,"Seminars in neurology 33 (01), 066-073",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10451702882896455944,36,2013
T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques …,"JI O'Riordan, MG Cain, A Coles, L Wang, DAS Compston, P Tofts, ...","Multiple Sclerosis Journal 4 (5), 408-412",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=341413922439651923,36,1998
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients,"G Giovannoni, JA Cohen, AJ Coles, HP Hartung, E Havrdova, KW Selmaj, ...","Neurology 87 (19), 1985-1992",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5792788919093591054,34,2016
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis,"L Azzopardi, SAJ Thompson, KE Harding, M Cossburn, N Robertson, ...","J Neurol Neurosurg Psychiatry 85 (7), 795-798",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13980729550568001054,33,2014
Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation,"RL Goya, R Busch, R Mathur, AJ Coles, RA Barker","Neurobiology of Disease 41 (2), 407-414",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11527985454893510889,31,2011
Future MS care: a consensus statement of the MS in the 21st Century Steering Group,"P Rieckmann, A Boyko, D Centonze, A Coles, I Elovaara, E Havrdová, ...","Journal of neurology 260 (2), 462-469",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9823677379486169678,30,2013
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis,"JWL Brown, AJ Coles","Drug design, development and therapy 7, 131",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10058145673292010809,29,2013
Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis,"D Meyer, A Coles, P Oyuela, A Purvis, DH Margolin","Multiple sclerosis and related disorders 2 (1), 60-63",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11510018653943121566,28,2013
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series,"L Azzopardi, AL Cox, CL McCarthy, JL Jones, AJ Coles","Journal of neurology 263 (1), 25-29",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15237930903377010943,25,2016
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab,"T Button, D Altmann, D Tozer, C Dalton, K Hunter, A Compston, A Coles, ...","Multiple Sclerosis Journal 19 (2), 241-244",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9403477030423582425,24,2013
Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab,"J Barton, TA Hardy, S Riminton, SW Reddel, Y Barnett, A Coles, ...","Neurology 88 (10), 1004-1006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14212925300772866415,22,2017
Monoclonal antibodies in multiple sclerosis treatment: current and future steps,"CL Helliwell, AJ Coles","Therapeutic advances in neurological disorders 2 (4), 195-203",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5505996707197189555,20,2009
Rationale for cytotoxic monoclonal antibodies in MS.,"BS Simpson, AJ Coles","International MS journal 14 (2), 48-56",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1934773840297818776,20,2007
Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features,"N Pariani, M Willis, I Muller, S Healy, T Nasser, A McGowan, G Lyons, ...","The Journal of Clinical Endocrinology & Metabolism 103 (8), 3010-3018",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1629846630456567808,19,2018
Efficacy of alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223,AJ Coles,"Neurology 68 (12), A100-A100",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9859756707951235707,19,2007
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab,"M Saarela, K Senthil, J Jones, PJ Tienari, M Soilu-Hänninen, L Airas, ...","Neurology 90 (18), 849-851",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12858825115383539163,18,2018
Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis,"JWL Brown, PJ Martin, JW Thorpe, AW Michell, AJ Coles, AL Cox, ...","Journal of neuroimmunology 271 (1-2), 66-68",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2754198384770243445,17,2014
"Detection, incidence and management of glomerulonephritis in the alemtuzumab clinical development programme","D Wynn, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 253-254",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15811027702939244051,17,2013
Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not …,"E Havrdova, DL Arnold, JA Cohen, DAS Compston, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 21, 45-46",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4276219174321706343,16,2015
Newer therapies for multiple sclerosis,A Coles,"Annals of Indian Academy of Neurology 18 (Suppl 1), S30",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4272905616436707374,16,2015
Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta 1a,AJ Coles,"Multiple Sclerosis 13, S166-S166",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=309316500665346160,16,2007
Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells,"I Smets, B Fiddes, JE Garcia-Perez, D He, K Mallants, W Liao, J Dooley, ...","Brain 141 (3), 786-796","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4295261045859878603,12792728719384194251",15,2018
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS,"DL Arnold, E Fisher, VV Brinar, JA Cohen, AJ Coles, G Giovannoni, ...","Neurology 87 (14), 1464-1472",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9159879652211284238,15,2016
When should placebo surgery as a control in clinical trials be carried out?,"AJT George, C Collett, AJ Carr, S Holm, C Bale, S Burton, M Campbell, ...","The Bulletin of the Royal College of Surgeons of England 98 (2), 75-79",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1228709964141022586,15,2016
Durable efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who participated in the CARE-MS studies: Three year follow-up (S41. 001),"E Fox, D Arnold, J Cohen, A Coles, C Confavreux, H Hartung, E Havrdova, ...","Neurology 80 (7 Supplement), S41. 001-S41. 001",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15124386034785924613,15,2013
Recurrent myelitis and optic neuritis in a 29-year-old woman,"A Cox, A Coles, N Antoun, O Malik, C Lucchinnetti, A Compston","The Lancet Neurology 4 (8), 510-516",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5596441404558688913,15,2005
No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL),"SA Broadley, SJ Sawcer, SJS Chataway, F Coraddu, A Coles, J Gray, ...","Journal of Neurology, Neurosurgery & Psychiatry 71 (1), 97-99",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3130751492809337111,15,2001
Quantifying normal human brain metabolism using hyperpolarized [1–13C] pyruvate and magnetic resonance imaging,"JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, ...","NeuroImage 189, 171-179",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4834676850185781372,14,2019
Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study,"AJ Coles, DL Arnold, JA Cohen, EJ Fox, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 20, 107-108",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4610905058537771700,14,2014
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects,"O Kousin-Ezewu, A Coles","Therapeutic advances in chronic disease 4 (3), 97-103",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12512884207181053905,14,2013
Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis,"DR Altmann, T Button, K Schmierer, K Hunter, DJ Tozer, ...","Multiple sclerosis and related disorders 3 (2), 237-243",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18353127703470379620,13,2014
Multiple sclerosis treatment trial precipitates divorce,"A Coles, J Deans, A Compston","Journal of neurology, neurosurgery, and psychiatry 70 (1), 135",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10989088409863068457,13,2001
Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of …,"AJ Coles, AN Boyko, JA Cohen, J De Seze, EJ Fox, E Havrdova, ...",SAGE PUBLICATIONS LTD,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6098644750425052728,12,2016
Durable effect of alemtuzumab on MRI activity in treatment-naive active relapsing-remitting multiple sclerosis patients: 4-year follow-up of CARE-MS I (P7. 246),"D Arnold, A Traboulsee, A Coles, J Cohen, E Fox, HP Hartung, ...","Neurology 84 (14 Supplement), P7. 246",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12317586499811409436,11,2015
First use of alemtuzumab in Balo’s concentric sclerosis: a case report,"JWL Brown, AJ Coles, JL Jones","Multiple Sclerosis Journal 19 (12), 1673-1675","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12598960902877672581,16805837345441506748",11,2013
"God, theologian and humble neurologist",A Coles,"Brain 131 (7), 1953-1959",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2310206124682395636,11,2008
Alemtuzumab compared with subcutaneous nigh-dose IFNB-1a in treatment-naive relapsing-remitting multiple sclerosis: Primary efficacy outcomes of CamMS223 at 3 years,A Coles,"Neurology 70 (11), A228-A228",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13284784192771564515,11,2008
Sarcoidosis following alemtuzumab treatment for multiple sclerosis,"MD Willis, B Hope-Gill, P Flood-Page, F Joseph, E Needham, J Jones, ...","Multiple Sclerosis Journal 24 (13), 1779-1782",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7511060562021661035,10,2018
Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation,"GM Khandaker, BP Oltean, M Kaser, CRM Dibben, R Ramana, DR Jadon, ...","BMJ open 8 (9), e025333",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5293949560404334606,10,2018
Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2,"ML Pekalski, AR García, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, ...",JCI insight 2 (16),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13105921708712802817,10,2017
Efficacy and safety of alemtuzumab in patients with RRMS is durable over 10 years: follow-up from the CAMMS223 study (P5. 338),"KW Selmaj, M Habek, A Bass, D Brassat, V Brinar, AJ Coles, A Vladic, ...","Neurology 88 (16 Supplement), P5. 338",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17784022404173955498,10,2017
Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of …,"EJ Fox, R Alroughani, D Brassat, S Broadley, JA Cohen, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 22, 596-597",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15880639974258940434,10,2016
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients,"EJ Fox, D Wynn, AJ Coles, J Palmer, DH Margolin, ...","Journal of the neurological sciences 363, 188-194",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6078919336184048679,10,2016
Durable Effect of Alemtuzumab on MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7. 249),"A Traboulsee, A Coles, J Cohen, DAS Compston, E Fox, HP Hartung, ...","Neurology 84 (14 Supplement), P7. 249",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5574923740552164534,10,2015
Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years,A Coles,"MULTIPLE SCLEROSIS 15 (9), S277-S277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9903632513189782370,10,2009
A case of stiff limb syndrome responsive to plasma exchange,"A Coles, R Barker","Journal of Neurology, Neurosurgery & Psychiatry 70 (3), 407-408",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9220199932980414331,10,2001
Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year …,"A Coles, D Arnold, J Cohen, E Fox, G Giovannoni, HP Hartung, ...","Neurology 86 (16 Supplement), P3. 022",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11538344713066800670,9,2016
Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-beta-1a,"A Coles, V Brinar, DL Arnold, J Cohen, C Confavreux, EJ Fox, HP Hartung, ...","Mult. Scler. J 17, S507-S524",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14186565856617916927,9,2011
Coles,A Compston,"Multiple sclerosis. Lancet 372, 1502-1517",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16788943630555829383,9,2008
Case reports in the Lancet,"A Coles, M Mukherjee, A Compston","The Lancet 361 (9364), 1230",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7984416521641292350,9,2003
"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","S Wray, E Havrdova, DR Snydman, DL Arnold, JA Cohen, AJ Coles, ...","Multiple Sclerosis Journal 25 (12), 1605-1617",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16839178884371393111,8,2019
Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years,"EJ Fox, DL Arnold, JA Cohen, AJ Coles, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 21, 570-570",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14236024353257113648,8,2015
Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study,"HP Hartung, DL Arnold, JA Cohen, AJ Coles, EJ Fox, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 20, 85-86",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16277796938778244131,8,2014
"Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: a CARE-MS substudy","DH Margolin, MA Rizzo, G Smith, DL Arnold, JA Cohen, AJ Coles, ...","Journal of the Neurological Sciences 333, e375-e376",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13040091899841695263,8,2013
The fragile benefit of BENEFIT,A Coles,"The Lancet Neurology 9 (6), 753-754",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3493631387077229178,8,2007
Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy,"AJ Coles, MG Wing, DAS Compston","Multiple Sclerosis Journal 4 (3), 232-238",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3383210809117063791,8,1998
Women on multiple sclerosis clinical trial steering committees,"J Moneim, A Coles, G Giovannoni, R Horne, O Carr","Annals of neurology 84 (2), 329-330",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8570262123736122389,7,2018
Durable Efficacy of Alemtuzumab Over 10 Years: Long-Term Follow-Up of Patients with RRMS from the CAMMS223 Study (P3. 053),"A Coles, M Habek, A Bass, V Brinar, A Vladic, D Margolin, M Lu, E Fox","Neurology 86 (16 Supplement), P3. 053",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=84707437989630976,7,2016
Incidence of Infection Decreases Over Time in Alemtuzumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 4-Year Follow-up of the CARE-MS Studies (P7. 265),"L Jung Henson, D Arnold, J Cohen, A Coles, E Fox, HP Hartung",Neurology 84 (14 Supplement),"https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4130248341453576895,6703360845948847029",7,2015
The outlook for alemtuzumab in multiple sclerosis,"T Williams, A Coles, L Azzopardi","BioDrugs 27 (3), 181-189",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15171796988556313259,7,2013
Two-year interim analysis of thyroid abnormalities in a trial of alemtuzumab vs. high-dose interferon beta-1a for treatment of relapsing-remitting multiple sclerosis,AJ Coles,"Neurology 68 (12), A277-A277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5293884823423705536,7,2007
The curious incident of disability in multiple sclerosis trials,A Coles,"The Lancet Neurology 5 (11), 899-900",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17938458007915320546,7,2006
"Looks like multiple sclerosis, but the ANA is positive: does my patient have lupus?",A Coles,"Practical neurology 4 (4), 212-221",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11146512296160632746,7,2004
Clinical Neurology,A Coles,"Journal of neurology, neurosurgery, and psychiatry 66 (2), 257",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15268730986962315299,7,1999
Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1),"BR Lennox, G Tomei, SA Vincent, K Yeeles, R Pollard, E Palmer-Cooper, ...","J Neurol Neurosurg Psychiatry 90 (3), 365-367",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3843180447181279737,6,2019
"Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects–a randomized, double‐blind, placebo‐controlled study","J Ellis, A van Maurik, L Fortunato, S Gisbert, K Chen, A Schwartz, ...","British journal of clinical pharmacology 85 (2), 304-315",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14508006450927022700,6,2019
Durable improvements in clinical outcomes with alemtuzumab in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS II patients (TOPAZ …,"BV Singer, R Alroughani, D Brassat, S Broadley, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 23, 366-367",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1094921875441828788,6,2017
Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study),"AJ Coles, AN Boyko, J De Seze, HP Hartung, E Havrdova, JS Inshasi, ...","Multiple Sclerosis Journal 23 (Suppl. 3), 627-628",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4709755458631609857,6,2017
Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies (P2. 086),"P Senior, D Arnold, J Cohen, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 86 (16 Supplement), P2. 086",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7115001377475639127,6,2016
Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7. 276),"E Havrdova, G Giovannoni, D Arnold, A Coles, E Fox, HP Hartung, ...","Neurology 84 (14 Supplement), P7. 276",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1190238796091365923,6,2015
Product licences for alemtuzumab and multiple sclerosis,"AJ Coles, A Compston","The Lancet 383 (9920), 867-868",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12975563989147483038,6,2014
"Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS; remitting multiple sclerosis (RRMS; CARE-MS I study)","J Lycke, DL Arnold, JA Cohen, AJ Coles, C Confavreux, EJ Fox, ...","Journal of the Neurological Sciences 333, e374-e375",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1589901794673788102,6,2013
Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS II study,"LH Kasper, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 217-218",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1388353338237720751,6,2013
"Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis","R Phelps, JA Winston, D Wynn, M Habek, HP Hartung, EK Havrdová, ...","Multiple Sclerosis Journal, 1352458519841829",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9722199721061736833,5,2019
The immunological response to traumatic brain injury,"EJ Needham, A Helmy, ER Zanier, JL Jones, AJ Coles, DK Menon",Journal of neuroimmunology,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2377189025835102609,5,2019
Authorship of phase 3 trials in multiple sclerosis.,A Coles,,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16392955131568840382,5,2018
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3. 054),"G Giovannoni, D Arnold, J Cohen, A Coles, E Fox, HP Hartung, ...","Neurology 86 (16 Supplement), P3. 054",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15496149667436765066,5,2016
Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension …,"S Schippling, J Cohen, A Coles, DA Compston, E Fox, M Filippi, ...","Neurology 86 (16 Supplement), S51. 001",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12444264001271745735,5,2016
Detection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development program,"B Lecumberri, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 21, 579-580",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13188212889111710062,5,2015
Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE MS …,"F Barkhof, JA Cohen, AJ Coles, DAS Compston, M Filippi, EJ Fox, ...","MULTIPLE SCLEROSIS JOURNAL 21, 44-45",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4706254074245796669,5,2015
Detection and management of immune thrombocytopenia in alemtuzumab-treated patients in the multiple sclerosis clinical development program,"A Cuker, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 21, 279-280",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6970961016101948047,5,2015
Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4. 007),"A Compston, G Giovannoni, D Arnold, E Fox, HP Hartung, E Havrdova, ...","Neurology 84 (14 Supplement), S4. 007",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6919486834315115911,5,2015
Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7. 263),"A Coles, D Arnold, J Cohen, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 84 (14 Supplement), P7. 263",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3119141987757365108,5,2015
Immunogenicity of alemtuzumab does not impact safety and efficacy in relapsing remitting multiple sclerosis patients in the CARE-MS I study,"T Ziemssen, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","Multiple Sclerosis Journal 19 (11), 212-213",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18211660380953170554,5,2013
Alemtuzumab pharmacokinetics and pharmacodynamics in comparison of Alemtuzumab and Rebif (R) efficacy in multiple sclerosis,"I Kovarova, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 259, S67-S67",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16490724835497429902,5,2012
Thyroid autoimmunity in comparison of Alemtuzumab and Rebif (R) efficacy in multiple sclerosis studies I and II,"M Habek, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","Journal of Neurology 259, S66-S66",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6036662535140896031,5,2012
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve …,"A Coles, V Brinar, D Arnold, J Cohen, C Confavreux, E Fox, H Hartung, ...","Neurology 78 (1 Supplement), S01. 006-S01. 006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11338734300285099339,5,2012
Predicting autoimmunity following treatment of multiple sclerosis with alemtuzumab,"JL Jones, DAS Compston, AJ Coles","Multiple Sclerosis Journal 17, S459-S459",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16293193067932231389,5,2011
Unilateral calf hypertrophy,"A Coles, D Dick","Journal of Neurology, Neurosurgery & Psychiatry 75 (11), 1606-1606",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5499055498634617787,5,2004
A JOURNAL OF NEUROLOGY,"DJ Webber, DA Compston, AJ Coles, L Jones",,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7993088711681636219,5,1997
A Commentary,"A Cores, U Flakes","Lithic Technology 16 (2-3), 51-53",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8828896112632478149,5,1987
Efficacy and safety of alemtuzumab in patients with RRMS is durable over 10 years: follow-up from the CAMMS223 Study,"KW Selmaj, M Habek, AD Bass, D Brassat, V Brinar, AJ Coles, A Vladic, ...","MULTIPLE SCLEROSIS JOURNAL 22, 325-326",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16610713798331521889,4,2016
RRMS patients switching from SC IFNB-1a to alemtuzumab in the CARE-MS I and II extension study have a reduced rate of brain volume loss (P6. 183),"F Barkhof, J Cohen, A Coles, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 86 (16 Supplement), P6. 183",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6887874181991629270,4,2016
"Parkinson's Disease, Religion, and Spirituality","C Redfern, A Coles","Movement disorders clinical practice 2 (4), 341-346",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5627656632658472270,4,2015
"Administration of Alemtuzumab on Nonconsecutive Days Does Not Impact Infusion-Associated Reactions, Efficacy, or Lymphocyte Depletion (P7. 277)","S Wray, A Boyko, T Braley, O Khan, D Margolin, J Palmer, A Coles","Neurology 84 (14 Supplement), P7. 277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=454483684953397810,4,2015
The Efficacy of Alemtuzumab Is Maintained in Patients Who Develop Thyroid Adverse Events (P7. 272),"S Hunter, D Arnold, A Coles, J Cohen, E Fox, HP Hartung, E Havrdova, ...","Neurology 84 (14 Supplement), P7. 272",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5470551279209192757,4,2015
Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS; remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE-MS I study,"LJ Balcer, DL Arnold, JA Cohen, AJ Coles, C Confavreux, EJ Fox, ...","Journal of the Neurological Sciences 333, e375",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=400122438301549649,4,2013
Alemtuzumab improves quality of life compared to SC IFNB-1a in CARE-MS II,"R Arroyo, DL Arnold, JA Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 260, S121-S122",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11452314601816591880,4,2013
Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II …,"C LaGanke, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 80 (7 Supplement), P01. 174-P01. 174",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16682586787224902055,4,2013
"Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis (CARE-MS) I and II (P01. 173)","T Miller, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 80 (7 Supplement), P01. 173-P01. 173",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9623406600725024568,4,2013
Alemtuzumab-associated infusion reactions in CARE-MS II: P2733,"A Boyko, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, HP Hartung, ...",European Journal of Neurology 19,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6509668751154953568,4,2012
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis I (CARE-MS I)(S41. 006),"K Selmaj, D Arnold, V Brinar, J Cohen, A Coles, C Confavreux, E Fox, ...","Neurology 78 (1 Supplement), S41. 006-S41. 006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5697821922376053344,4,2012
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple …,"J Cohen, C Twyman, D Arnold, A Coles, C Confavreux, E Fox, H Hartung, ...",NEUROLOGY 78,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12152610466086882593,4,2012
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis is independent of baseline status,AJ Coles,"JOURNAL OF NEUROLOGY 254, 55-55",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3003619636616082762,4,2007
Notes on the kidney and its diseases for the neurologist,"MS Zandi, AJ Coles","Journal of Neurology, Neurosurgery & Psychiatry 78 (5), 444-449",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14010110060430434631,4,2007
Anti-lymphocyte monoclonal antibody treatment of multiple sclerosis suppresses disease activity but induces Graves' disease,"AJ Coles, MG Wing, G Hale, H Waldmann, AP Weetman, DAS Compston, ...","Journal of Endocrinological Investigation 21, 3-3",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9700317134604203302,4,1998
Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI,"JT Grist, F Riemer, MA McLean, T Matys, F Zaccagna, SF Hilborne, ...","Journal of the neurological sciences 387, 111-114",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15389095419530274483,3,2018
Alemtuzumab as Treatment for Multiple Sclerosis.,"S Katsavos, A Coles",,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6273176811573890859,3,2018
Hypothyroid ataxia complicating monoclonal antibody therapy,"A Badran, C Moran, AJ Coles","Practical neurology 17 (6), 482-484",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14699787598656913831,3,2017
Increased THEMIS first exon usage in CD4+ T-cells is associated with a genotype that is protective against multiple sclerosis,"JL Davies, S Thompson, H Kaur-Sandhu, S Sawcer, A Coles, M Ban, ...","PloS one 11 (7), e0158327",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11909518666127462144,3,2016
Alemtuzumab use in neuromyelitis optica spectrum disorders-a brief case series,"L Azzopardi, AL Cox, C Mccarthy, JL Jones, AJ Coles","MULTIPLE SCLEROSIS JOURNAL 21, 554-555",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8028518524031325647,3,2015
Timing is everything in the treatment of multiple sclerosis,"CL McCarthy, G Giovannoni, AJ Coles","BMJ case reports 2015, bcr2014208960",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1232513431276992027,3,2015
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study,"X Montalban, JS Inshasi, AJ Coles, HP Hartung, E Havrdova, KW Selmaj, ...","Multiple sclerosis and related disorders 3 (6), 761-762",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10544840358133092487,3,2014
Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up,"J Lycke, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 487-488",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10258923268483569100,3,2013
Infection risk with alemtuzumab in patients with relapsing remitting multiple sclerosis: pooled results from the CARE-MS I and CARE-MS II trials,"E Havrdova, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 257-258",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1100036341248965529,3,2013
Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II),"E Havrdova, DL Arnold, JA Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 260, S120-S120",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4797382669936446604,3,2013
Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis,"EJ Fox, DL Arnold, J Cohen, AJ Coles, C Confavreux, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 18, 465-466",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8070488463899358059,3,2012
"Effect of Alemtuzumab vs. Rebif® on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11. 006)","D Arnold, V Brinar, J Cohen, A Coles, C Confavreux, E Fisher, E Fox, ...","Neurology 78 (1 Supplement), S11. 006-S11. 006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17521140365007576847,3,2012
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis …,"J Cohen, C Twyman, D Arnold, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 78 (1 Supplement), S01. 004-S01. 004",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14511878429877690910,3,2012
"Effect of Alemtuzumab vs. Rebif (R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study","D Arnold, V Brinar, J Cohen, A Coles, C Confavreux, E Fisher, E Fox, ...",NEUROLOGY 78,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3568419144532832016,3,2012
Peripheral expansion dominates early T cell reconstitution following alemtuzumab treatment of multiple sclerosis-implications for secondary autoimmunity,"SAJ Thompson, AJ Coles, JL Jones","Multiple Sclerosis Journal 17, S191-S192",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4569076883057512238,3,2011
Can the course of multiple sclerosis be modified?,A Coles,"Practical Neurology 5 (5), 278-287",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=562095900234382840,3,2005
Neutralising antibodies to the beta interferons,AJ Coles,"Journal of Neurology, Neurosurgery & Psychiatry 73 (2), 110-111",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17618289081180971589,3,2002
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis,"AJ Coles, A Paolillo, P Molyneux, MG Wing, G Hale, D Miller, ...","ANNALS OF NEUROLOGY 44 (3), 464-464",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5339614995243938344,3,1998
Promoting remyelination in multiple sclerosis,"N Cunniffe, A Coles","Journal of neurology, 1-15",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9664934131696070454,2,2019
A case of anaphylaxis to alemtuzumab,"CJS Nye, A Wagner, O Kousin-Ezewu, JL Jones, AJ Coles","Journal of neurology 266 (3), 780-781",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2753327389901601123,2,2019
Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)(P6. 376),"P Vermersch, AJ Coles, AN Boyko, J De Seze, HP Hartung, E Havrdova, ...","Neurology 90 (15 Supplement), P6. 376",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7985100894670396276,2,2018
Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study)(P6. 369),"BA Singer, R Alroughani, D Brassat, S Broadley, HP Hartung, E Havrdova, ...","Neurology 90 (15 Supplement), P6. 369",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1607989978803697988,2,2018
Fatigue bei Multipler Sklerose: Neuronale Korrelate und Möglichkeiten nicht-invasiver Hirnstimulation mit tDCS,"SS Ayache, MA Chalah, T Kümpfel, F Padberg, JP Lefaucheur, U Palm","Fortschritte der Neurologie· Psychiatrie 85 (05), 260-269",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11880653495328064433,2,2017
Meeting abstracts from the 64th British Thyroid Association Annual Meeting,"L Bartalena, E Fliers, N Hellen, PN Taylor, A Lacey, D Thayer, MD Yusof, ...","Thyroid Research 10 (1), 2",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15657332549289246785,2,2017
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3. 059),"H Wiendl, D Arnold, J Cohen, A Coles, E Fox, HP Hartung, E Havrdova, ...","Neurology 86 (16 Supplement), P3. 059",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18389314971158731792,2,2016
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51. 005),"E Fox, D Arnold, J Cohen, G Giovannoni, HP Hartung, E Havrdova, ...","Neurology 86 (16 Supplement), S51. 005",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5716695630145447695,2,2016
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I …,"V Limmroth, G Giovannoni, D Arnold, J Cohen, A Coles, E Fox, ...","Neurology 86 (16 Supplement), S51. 004",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8202643124814169661,2,2016
Treatment-Naive Patients with Active RRMS Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS I Study (S51. 002),"D Arnold, J Cohen, A Coles, DA Compston, E Fox, HP Hartung, ...","Neurology 86 (16 Supplement), S51. 002",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16208011289007778745,2,2016
"Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a","T Kalincik, JW Brown, N Robertson, M Willis, N Scolding, O Pearson, ...","Multiple Sclerosis Journal 22, 829-832",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15112346646482295273,2,2016
Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years,"DL Arnold, A Traboulsee, JA Cohen, AJ Coles, EJ Fox, G Giovannoni, ...","MULTIPLE SCLEROSIS JOURNAL 21, 568-569",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16889453582780912859,2,2015
Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS I Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7. 261),"F Barkhof, D Pelletier, A Coles, J Cohen, DAS Compston, E Fox, ...","Neurology 84 (14 Supplement), P7. 261",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=481242010554269432,2,2015
Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7. 264),"J Cohen, D Arnold, A Coles, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 84 (14 Supplement), P7. 264",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10129946980446559282,2,2015
Improvement in Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients Who Switched From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7. 270),"HP Hartung, G Giovannoni, D Arnold, A Coles, E Fox, E Havrdova, ...","Neurology 84 (14 Supplement), P7. 270",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8237022097677913627,2,2015
Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS II Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7. 248),"D Pelletier, F Barkhof, A Coles, J Cohen, A Compston, E Fox, HP Hartung, ...","Neurology 84 (14 Supplement), P7. 248",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17328616503809154594,2,2015
Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7. 278),"E Fox, G Giovannoni, D Arnold, A Coles, HP Hartung, E Havrdova, ...","Neurology 84 (14 Supplement), P7. 278",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=825531315312105219,2,2015
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study,"BC Kieseier, MA Sahraian, AJ Coles, HP Hartung, E Havrdova, ...","Multiple sclerosis and related disorders 3 (6), 756",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=812079086439192879,2,2014
Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II,"O Fernandez, DL Arnold, JA Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 260, S14-S14",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17455501853215930210,2,2013
Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II)(P07 …,"C Twyman, X Montalban, D Arnold, J Cohen, A Coles, C Confavreux, ...","Neurology 80 (7 Supplement), P07. 098-P07. 098",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16259674994569457212,2,2013
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy: SC345,"C Confavreux, C Twyman, D Arnold, J Cohen, A Coles, E Fox, ...",European Journal of Neurology 19,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5942079803612989159,2,2012
Encephalitis and schizophrenia: a matter of words,"K O'Loughlin, P Ruge, MD McCauley","The British Journal of Psychiatry 201 (1), 74-74",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8200446402720316253,2,2012
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I)(S41. 007),"E Havrdova, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 78 (1 Supplement), S41. 007-S41. 007",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9509820097598058216,2,2012
The ethical issues of trials of neural grafting in patients with neurodegenerative conditions,"RA Barker, A Coles",Oxford Handbook of Neuroethics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17975447886324763267,2,2011
POI06 Rituximab in neuropsychiatric systemic lupus erythematosus: a retrospective study of the Cambridge experience,"M Zandi, F Catapano, S Burns, FC Hall, KGC Smith, DRW Jayne, ...","Journal of Neurology, Neurosurgery & Psychiatry 81 (11), e54-e54",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14053453499947120448,2,2010
Leukocyte dynamics following alemtuzumab treatment of relapsing-remitting multiple sclerosis in a phase 2 study (CAMMS223),A Coles,"Neurology 74 (9), A553-A553",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7027627842140841349,2,2010
Alemtuzumab for the treatment of multiple sclerosis,"T Button, AJ Coles","Future Neurology 5 (2), 177-188",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11667623377362013763,2,2010
Alemtuzumab (campath-1H) treatment for multiple sclerosis reduces pro-inflammatory cytokine secretion from peripheral blood mononuclear cells,"CL Helliwell, SAJ Thompson, J Jones, JA Somerfield, M Zandi, ...",JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 80 (11),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10731884241008859079,2,2009
Trials of diminishing relapses for diminishing returns.,A Coles,"The Lancet. Neurology 8 (10), 870-871",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13799749684789044171,2,2009
Fit to decide?,"AJ Coles, AJ Coles","Brain 132 (5), 1407-1410",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16611131964772827010,2,2009
Alemtuzumab Induces a Sustained Reduction in Disability in Patients with Relapsing Remitting Multiple Sclerosis,AJ Coles,"NEUROLOGY 72 (11), A318-A318",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9313718038036397876,2,2009
"Anti-GAD65, NMDAR and VGKC antibodies detected in first episode psychosis","B Lennox, M Zandi, S Irani, AJ Coles, A Vincent",SCHIZOPHRENIA BULLETIN 35,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9110338414942656532,2,2009
Consistent efficacy with early use of alemtuzumab in relapsing-remitting multiple sclerosis across major demographic subgroups,A Coles,"JOURNAL OF NEUROLOGY 255, 45-46",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15539726618208539984,2,2008
"Neurology of the Arts: Painting, Music, Literature",A Coles,"Journal of Neurology 252 (1), 116-116",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2177219101696656064,2,2005
Neurologic complications in organ transplant recipients,A Coles,"Journal of Neurology, Neurosurgery & Psychiatry 68 (1), 123-123",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6248890354051599335,2,2000
Immune responses and the nervous system,"A Coles, N Scolding",Immunological and Inflammatory Disorders of the Central Nervous System …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3941720910775467439,2,1999
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled …,"B Lennox, K Yeeles, PB Jones, M Zandi, E Joyce, LM Yu, G Tomei, ...","Trials 20 (1), 331",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18400130663240983124,1,2019
Plasma cell depletion with bortezomib in the treatment of refractory ,"S Keddie, SJ Crisp, J Blackaby, A Cox, A Coles, M Hart, AJ Church, ...","European journal of neurology 25 (11), 1384-1388",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17094696649327407752,1,2018
A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers,"AM Mori, S Agarwal, MWM Lee, M Rafferty, TA Hardy, A Coles, ...","Journal of neuroimmunology 312, 4-7",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3921996589302784721,1,2017
Physician-assisted death should be available to people with MS–Commentary,A Coles,"Multiple Sclerosis Journal 23 (13), 1681-1681",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17572133399509392821,1,2017
Improvements in clinical outcomes with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis are durable over 6 years in the absence of …,"B Singer, AJ Coles, AN Boyko, JA Cohen, J De Seze, EJ Fox, E Havrdova, ...","Neurology 88 (16 Supplement), S24. 005",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13970274354925157642,1,2017
Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology.,"S Agarwal, J Patrick, JL Jones, RM Smith, AJ Coles, DR Jayne",Oxford University Press,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7576982917917882432,1,2017
Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS I Extension Study Show Durable Reduction in New Lesion Activity (P3. 026),"A Rovira, J Cohen, A Coles, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 86 (16 Supplement), P3. 026",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15353187626753529629,1,2016
Patients Who Switched from SC IFNB-1a to Alemtuzumab in the CARE-MS II Extension Study Show Durable Improvements in Clinical Outcomes (P3. 024),"E Havrdova, D Arnold, J Cohen, A Coles, E Fox, HP Hartung, K Selmaj, ...","Neurology 86 (16 Supplement), P3. 024",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8324008747517323789,1,2016
Patients with Active RRMS and an Inadequate Response to Prior Therapy Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of …,"A Traboulsee, J Cohen, A Coles, DA Compston, E Fox, HP Hartung, ...","Neurology 86 (16 Supplement), P3. 112",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15593228604837020168,1,2016
"Recent thymic emigrants produce antimicrobial IL-8, express complement receptors and are precursors of a tissue-homing Th8-like memory subset","ML Pekalski, AR García, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, ...","bioRxiv, 059535",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14541996434824962868,1,2016
Complement receptor 2 and IL-8 production identifies in adults and neonates naïve T cells recently arising from the thymus,"ML Pekalski, AR Garcia, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, ...","bioRxiv, 059535",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5684394070397926778,1,2016
Management of adverse reactions to alemtuzumab infusion,"B Sharrack, L Mayer, A Coles, HP Hartung, E Havrdova, K Selmaj, ...","J Neurol Neurosurg Psychiatry 86 (11), e4-e4",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13982858732620629120,1,2015
Alemtuzumab in multiple sclerosis: long-term follow-up of the early cohorts,"JWL Brown, O Tuohy, O Kousin-Ezewu, L Azzopardi, T Button, C Mccarthy, ...","MULTIPLE SCLEROSIS JOURNAL 21, 790-791",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6228919780235467561,1,2015
Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years,"A Traboulsee, JA Cohen, AJ Coles, DAS Compston, EJ Fox, ...","MULTIPLE SCLEROSIS JOURNAL 21, 570-571",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=164355421131645788,1,2015
Durable Efficacy of Alemtuzumab in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P7. 269),"B Singer, E Fox, S Krieger, HP Hartung, L Amezcua, D Margolin, L Kasten, ...","Neurology 84 (14 Supplement), P7. 269",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6897329714258149766,1,2015
Lymphocyte Counts Do Not Predict Risk of Subsequent Relapse or Disability Accumulation in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients: An Analysis of …,"A Coles, J Palmer, D Margolin","Neurology 82 (10 Supplement), P3. 181",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14275319268345947963,1,2014
NMDA receptor antibodies in first episode psychosis: prevalence and clinical phenotype,"B Lennox, MS Zandi, JB Deakin, A Coles, L Scoriels, P Jones, E Coutinho, ...","Schizophrenia Research, S35",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17530292236046424539,1,2014
ACUTE BACTERIAL MENINGITIS MANAGEMENT IN ADULTS IS INADEQUATE: A MULTI–CENTRE AUDIT AND SURVEY,"EJ Needham, JW Brown, DNS Senaratne, AM Karimi, TA Gibson, ...","J Neurol Neurosurg Psychiatry 84 (11), e2-e2",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9041580023226290535,1,2013
Reduction of disability with alemtuzumab in relapsing remitting multiple sclerosis patients who participated in CARE-MS II: three year follow-up,"HP Hartung, DL Arnold, JA Cohen, AJ Coles, EJ Fox, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 250-250",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=199780298152277883,1,2013
Anti-IFNB-1a Antibody Status Was Not a Factor Influencing Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity …,"O Khan, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 80 (7 Supplement), P07. 125-P07. 125",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15647477089595231807,1,2013
Immunogenicity of alemtuzumab treatment in relapsing-remitting multiple sclerosis (RRMS) patients in the CARE-MS II Study (P07. 101),"P Soelberg-Sorensen, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, ...","Neurology 80 (7 Supplement), P07. 101-P07. 101",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14495034363643844925,1,2013
Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II)(P01. 172),"S Wray, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, H Hartung, ...","Neurology 80 (7 Supplement), P01. 172-P01. 172",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8712137919703584044,1,2013
Lymphocyte subset dynamics following alemtuzumab administration in the CARE-MS I trial: SC346,"J Lycke, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, HP Hartung, ...",European Journal of Neurology 19,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4049158906795300117,1,2012
Alemtuzumab improves patient-reported quality of life in relapsing-remitting multiple sclerosis: CARE-MS I and II phase 3 trials,"K Selmaj, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 259, S65-S66",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11733856858695238715,1,2012
Disease activity-free status in comparison of Alemtuzumab and Rebif (R) efficacy in multiple sclerosis I (CARE-MS I) phase 3 study,"G Giovannoni, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 259, S47-S47",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4955747969908574690,1,2012
Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE-MS II,"HP Hartung, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","JOURNAL OF NEUROLOGY 259, S47-S48",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3391487939324290924,1,2012
Relapse outcomes with alemtuzumab vs. Rebif® in treatment-naïve relapsing-remitting multiple sclerosis (CARE-MS I): secondary and tertiary endpoints (PD5. 004),"E Fox, D Arnold, V Brinar, J Cohen, A Coles, C Confavreux, G Giovannoni, ...","Neurology 78 (1 Supplement), PD5. 004-PD5. 004",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2008932622847576488,1,2012
Effect of Alemtuzumab versus Rebif on Brain MRI Measurements: Results of CARE-MS II,"DL Arnold, JA Cohen, AJ Coles, C Confavreux, E Fisher, EJ Fox, ...",29th Congress of the European Committee for Research and Treatment in …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13299029104280313539,1,2012
Alemtuzumab in Multiple Sclerosis.,"L Azzopardi, A Coles",Archives of Neuropsychiatry/Noropsikiatri Arsivi 48,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13300756036801112614,1,2011
Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis,"T Button, D Altmann, D Tozer, C Dalton, DAS Compston, D Miller, ...","MULTIPLE SCLEROSIS JOURNAL 17, S437-S437",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18279987754653521647,1,2011
Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab,"J Jones, A Compston, A Coles","Clinical Immunology, S103",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8184987223565818145,1,2010
Alemtuzumab reverses pre-existing disability in relapsing-remitting multiple sclerosis patients independent of relapse history,A Coles,"MULTIPLE SCLEROSIS 15 (9), S135-S135",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7116336846315483468,1,2009
Neurotrophin production by immune cells after immunotherapy for multiple sclerosis,"JL Jones, S Thompson, AL Cox, DAS Compston, AJ Coles","JOURNAL OF NEUROIMMUNOLOGY 154 (1-2), 212-212",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9786830917975893157,1,2004
Lymphocyte depletion in multiple sclerosis induces a relative increase in regulatory T cells,"A Cox, S Thompson, G Hale, H Waldman, D Compston, A Coles",Immunology-Supplement 110,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3526628326695282327,1,2003
CAMPATH-1H exposes three mechanisms underlying the natural history of multiple sclerosis in the individual patient,"DAS Compston, AJ Coles, DH Miller, H Waldmann","Journal of Neuroimmunology 90 (1), 96",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6774146424029913232,1,1998
Thyroid dysfunction following anti-lymphocyte monoclonal antibody treatment of multiple sclerosis-Scintigraphic assessment.,"KK Balan, AJ Coles, EP Wraight, VK Chatterjee, A Compston","JOURNAL OF NUCLEAR MEDICINE 39 (5), 263P-263P",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4979153472964300554,1,1998
"Temporal Dostoyevsky Significance Lobe and Epilepsy, Irrational",A Coles,"The Neurology of Religion, 89",,0,2019
The II The Discipline Natures of Neurology of Neurology,A Coles,"The Neurology of Religion, 1",,0,2019
The Neurology of Religion,"A Coles, J Collicutt",Cambridge University Press,,0,2019
Long-term efficacy and safety of Alemtuzumab in patients with RRMS: 12-year follow-up of the CAMMS223 study,"A Coles, R Berkovich, M Carraro, DAS Compston, Y Al Malik, ...","MULTIPLE SCLEROSIS JOURNAL 25, 320-321",,0,2019
"Autoantibody production following Traumatic Brain Injury is associated with poor outcome, and is therapeutically modifiable","E Needham, A Coles, DK Menon","EUROPEAN JOURNAL OF NEUROLOGY 26, 27-27",,0,2019
ADAPTIVE IMMUNE RESPONSES IN TRAUMATIC BRAIN INJURY,"D Menon, E Needham, A Helmy, P Hutchinson, K Wang, J Jones, A Coles","JOURNAL OF NEUROTRAUMA 36 (13), A119-A119",,0,2019
Keratinocyte growth factor impairs human thymic recovery from lymphopenia,"AJ Coles, L Azzopardi, O Kousin-Ezewu, HK Mullay, SAJ Thompson, ...",JCI insight 4 (12),,0,2019
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab,"JWL Brown, F Prados Carrasco, A Eshaghi, CH Sudre, T Button, ...","Multiple Sclerosis Journal, 1352458519852093",,0,2019
Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis,"J Gao, J Jones, EM Damato, A Coles","Journal of neurology 266 (6), 1539-1540",,0,2019
"1 The neurological, psychiatric and theological significance of mystical seizures",A Coles,"Journal of Neurology, Neurosurgery & Psychiatry 90 (Suppl 2), A1-A1",,0,2019
Author response to Dr. Jagannadha Avasarala,AJ Coles,,,0,2019
Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series,"JCP Roos, C Moran, VK Chatterjee, J Jones, A Coles, R Murthy","Eye 33 (2), 223",,0,2019
Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS,"T Kalincik, CB Malpas, S Sharmin, I Roos, F Patti, H Butzkueven, ...",SAGE PUBLICATIONS LTD,,0,2019
Sarcoidosis following alemtuzumab treatment for multiple sclerosis,"JL Jones, M Willis, AJ Coles",SAGE Publications,,0,2018
Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER …,"D Ontaneda, E Tallantyre, K Nakamura, SM Planchon, DM Miller, C Hersh, ...",SAGE Publications 24 (2),,0,2018
Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings,AJ Coles,"Neurology 91 (12), 581-582",,0,2018
Imaging the healthy human brain with hyperpolarized 13C MRI,"J Grist, MA McLean, F Riemer, F Zaccagna, SF Hilborne, JP Mason, ...",Wiley,,0,2018
Hemophagocytic Lymphohistiocytosis in 2 Multiple Sclerosis Patients Treated With Alemtuzumab,"M Saarela, K Senthil, J Jones, P Tienari, M Soilu-hanninen, L Airas, ...",Wolters Kluwer Health,,0,2018
Alemtuzumab: Paradoxical effects on autoimmunity in individuals MS,AJ Coles,ACTRIMS Forum 2018,,0,2018
Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study,"BA Singer, R Alroughani, D Brassat, S Broadley, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 24, 22-22",,0,2018
PO132 Clinical features of demyelination following anti-tnfΑ therapy,"P Hendy, N Heerasing, G Walker, J Goodhand, T Harrower, J Hobart, ...","J Neurol Neurosurg Psychiatry 88 (Suppl 1), A47-A47",,0,2017
Preventable side effects of Alemtuzumab,"N Scolding, A Coles","MULTIPLE SCLEROSIS JOURNAL 23, 62-62",,0,2017
The effect of alemtuzumab on periventricular magnetisation transfer ratio gradients,"JWL Brown, FP Carrasco, A Eshaghi, M Pardini, T Button, RS Samson, ...","MULTIPLE SCLEROSIS JOURNAL 23, 999-999",,0,2017
PWE-066 Clinical features of demyelination during anti-tnf therapy: preliminary outcomes of the pred4 study,"P Hendy, N Heerasing, G Walker, G Heap, C Bewshea, N Kennedy, ...","Gut 66 (Suppl 2), A159-A159",,0,2017
Bestätigt sich das Wirksamkeitsversprechen kontrollierter Studien von Alemtuzumab (Lemtrada®) in der täglichen Praxis?,J Havla,"Fortschritte der Neurologie· Psychiatrie 85 (06), 318-319",,0,2017
Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of …,"EJ Fox, D Brassat, R Alroughani, S Broadley, J Cohen, HP Hartung, ...","Neurology 88 (16 Supplement), S24. 006",,0,2017
P550 Clinical features of demyelination following anti-TNFα therapy,"P Hendy, N Heerasing, G Walker, G Heap, C Bewshae, N Kennedy, ...","Journal of Crohn's and Colitis 11 (suppl_1), S360-S360",,0,2017
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis,"JWL Brown, A Coles, D Horakova, E Havrdova, M Trojano, G Izquierdo, ...","Multiple Sclerosis Journal 23 (Suppl. 3), 32-34",,0,2017
Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis,"AJ Coles, JL Jones, A Compston","US Patent App. 15/013,808",,0,2016
Alemtuzumab Persistently Slows Brain Volume Loss In Rrms,"A Coles, D Arnold, F Barkhof, M Filippi, HP Hartung, E Havrdova, ...","J Neurol Neurosurg Psychiatry 87 (12), e1-e1",,0,2016
Treatment of multiple sclerosis (MS),"DH Margolin, W Hong, AJ Coles, A Compston, Z Shaked","US Patent 9,498,528",,0,2016
Graves,"N Pariani, M Willis, I Muller, S Healy, T Nasser, J Jones, VKK Chatterjee, ...",Society for Endocrinology BES 2016 44,,0,2016
Genotypic influences on surface expression of co-stimulatory receptors suggests a role for B-cell subtypes in the development of multiple sclerosis,"D He, B Fiddes, J Jones, W Liao, A Compston, A Coles, M Ban, S Sawcer","MULTIPLE SCLEROSIS JOURNAL 22, 93-94",,0,2016
Increased $\small\textit {THEMIS} $ First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis,"JL Davies, SA Thompson, H Kaur-Sandhu, SJ Sawcer, AJ Coles, M Ban, ...",Public Library of Science (PLoS),,0,2016
Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS II Extension Study Show Durable Reduction in New Lesion Activity (P3. 025),"D Pelletier, J Cohen, A Coles, E Fox, HP Hartung, E Havrdova, K Selmaj, ...","Neurology 86 (16 Supplement), P3. 025",,0,2016
Complement receptor 2 and IL-8 production identify in humans naïve T cells recently emigrating from the thymus and a Th8-like subset of memory T cells,"ML Pekalski, AR García, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, ...","bioRxiv, 059535",,0,2016
Alemtuzumab (Campath-1H),"A Coles, J Jones, A Compston","Translational Neuroimmunology in Multiple Sclerosis, 235-244",,0,2016
LONG-TERM SAFETY OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: PREGNANCY AND INFECTION DATA FROM A COHORT OF PATIENTS ON OPEN LABEL STUDIES IN CAMBRIDGE,"C McCarthy, O Tuohy, L Azzopardi, O Kousin-Ezewu, J Jones, ...","J Neurol Neurosurg Psychiatry 86 (11), e4-e4",,0,2015
ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II,"A Coles, G Giovannoni, T Moreau, E Havrdova, D Margolin, L Kasten, ...","J Neurol Neurosurg Psychiatry 86 (11), e4-e4",,0,2015
PARKINSON'S DISEASE AND SPIRITUALITY,"A Coles, C Redfern","J Neurol Neurosurg Psychiatry 86 (11), e4-e4",,0,2015
Lack of evidence for T-cell expression of siglec-10 and suppressive interaction with soluble CD52,"L Azzopardi, E Havari, M Turner, W Brondyk, D Reczek, Z Georgieva, ...","MULTIPLE SCLEROSIS JOURNAL 21, 547-547",,0,2015
Durable improvement in clinical outcomes with alemtuzumab following switch from subcutaneous interferon beta-1a in patients with active RRMS: three-year follow-up of the CARE …,"JA Cohen, DL Arnold, AJ Coles, EJ Fox, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 21, 569-570",,0,2015
Durable improvement in clinical outcomes with alemtuzumab following switch from subcutaneous interferon beta-1a in treatment-naive patients with active RRMS: three-year follow …,"HP Hartung, DL Arnold, JA Cohen, AJ Coles, EJ Fox, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 21, 565-566",,0,2015
Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study,"S Vucic, AJ Coles, DL Arnold, HP Hartung, E Havrdova, KW Selmaj, ...","MULTIPLE SCLEROSIS JOURNAL 21 (6), 821-821",,0,2015
Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study,"RAL Macdonell, AJ Coles, DL Arnold, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 21 (6), 806-806",,0,2015
The multiple sclerosis associated variant rs13204742 regulates first exon usage ofTHEMISin CD4+ T-cells,"J Davies, M Ban, K Sandhu, S Thompson, S Sawcer, A Coles, J Jones",Immunology 143,,0,2014
"Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome reports with SC interferon beta-1a","AF Amor, A Trochanov, J Johnson","Multiple sclerosis and related disorders 3 (6), 756-757",,0,2014
Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy,"LH Kasper, DL Arnold, AJ Coles, H Hartung, E Havrdova, KW Selmaj, ...","Journal of Neuroimmunology 275 (1), 63-64",,0,2014
Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective,"C Celestin, GR Cutter, AJ Coles, A Reimers, DH Margolin","MULTIPLE SCLEROSIS JOURNAL 20, 72-72",,0,2014
Durable Effect of Alemtuzumab on Relapse Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis: CARE-MS Three-Year Follow-Up,"SA Broadley, DL Arnold, JA Cohen, AJ Coles, EJ Fox, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 20 (7), 934-935",,0,2014
The functional role of genetic variants at theTHEMIS//PTPRKlocus in multiple sclerosis: 308,"J Davies, M Ban, S Thompson, J Jones, S Sawcer, A Coles",Immunology 140,,0,2013
Compensatory increase in mitochondrial trafficking induced by focal mitochondrial damage results in selective block of transport in small diameter axons,"M Sajic, KK Ida, NA Gregson, KJ Smith","Journal of the Neurological Sciences 333, e373-e374",,0,2013
Lymphocyte counts and efficacy outcomes after alemtuzumab in relapsing remitting multiple sclerosis patients: the CARE-MS studies,"PS Sorensen, DL Arnold, JA Cohen, EJ Fox, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 207-208",,0,2013
Alemtuzumab improves expanded disability status scale (EDSS) via effects on functional systems: CARE-MS II,"V Brinar, DL Arnold, J Cohen, AJ Coles, EJ Fox, HP Hartung, E Havrdova, ...","MULTIPLE SCLEROSIS JOURNAL 19 (11), 283-284",,0,2013
Differential lymphocyte reconstitution after treatment of relapsing-remitting multiple sclerosis with alemtuzumab is not linked to disease stability,"O Kousin-Ezewu, L Azzopardi, O Tuohy, R Parker, A Coles, J Jones","MULTIPLE SCLEROSIS JOURNAL 19 (11), 568-568",,0,2013
Multiple Sklerose–Alemtuzumab bei Rückfall nach Erstlinientherapie?,F Lichert,"Fortschritte der Neurologie· Psychiatrie 81 (05), 235-235",,0,2013
"30. Multiple Sclerosis: Ethics, Outcome Wariables and","AJ Coles, DAS Compston","Clinical Trials in Neurology, 359",,0,2013
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy,"H Hartung, T Vollmer, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, ...",NEUROLOGY 80,,0,2013
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07. 093),"H Hartung, T Vollmer, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, ...","Neurology 80 (7 Supplement), P07. 093-P07. 093",,0,2013
Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by …,"M Freedman, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, ...","Neurology 80 (7 Supplement), P07. 111-P07. 111",,0,2013
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE …,"G Giovannoni, D Arnold, J Cohen, A Coles, C Confavreux, E Fox, ...","Neurology 80 (7 Supplement), P07. 120-P07. 120",,0,2013
Targeting CD52 for the Treatment of Multiple Sclerosis,"A Coles, J Jones","Multiple Sclerosis Immunology, 385-399",,0,2013
An investigation into Adaptive Autoimmunity in Severe Traumatic Brain Injury,"A Krepska, A Curry, S Thompson, J Jones, A Coles, D Menon","JOURNAL OF NEUROIMMUNOLOGY 253 (1-2), 28-29",,0,2012
TWO INTERESTING CASES OF NMDAR ENCEPHALITIS AND A TYPICAL BUT SERONEGATIVE CASE WITH OVARIAN TERATOMA,"M Ellul, S Sawcer, AJ Coles, MS Zandi","Journal of Neurology, Neurosurgery and Psychiatry 83, A7",,0,2012
Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II),"E Havrdova, DL Arnold, J Cohen, AJ Coles, C Confavreux, EJ Fox, ...","MULTIPLE SCLEROSIS JOURNAL 18, 235-235",,0,2012
Effect of alemtuzumab vs. Rebif (R) on brain MRI measurements,"DL Arnold, J Cohen, AJ Coles, C Confavreux, E Fisher, EJ Fox, ...","MULTIPLE SCLEROSIS JOURNAL 18, 397-398",,0,2012
Disability improvement with alemtuzumab vs. interferon-beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II),"G Giovannoni, DL Arnold, J Cohen, AJ Coles, C Confavreux, E Fox, ...","MULTIPLE SCLEROSIS JOURNAL 18, 419-420",,0,2012
Sample sizes for lesion magnetisation transfer ratio outcome measures in remyelination trials for multiple sclerosis,"DR Altmann, T Button, K Schmierer, K Hunter, D Tozer, ...","Multiple Sclerosis Journal 18, 470-470",,0,2012
Encephalitis and schizophrenia: a matter of words reply,"BR Lennox, AJ Coles, A Vincent",BRITISH JOURNAL OF PSYCHIATRY 201 (1),,0,2012
"We are about to cure MS in the next 10 years, even though we do not know its cause: No",A Coles,"Multiple Sclerosis Journal 18 (6), 784-785",,0,2012
B-CELLS VS T-CELLS IN MS: ARE B-CELL DIRECTED TREATMENTS AS GOOD AS T-CELL DIRECTED? ARE THEY BETTER FOR SOME PATIENTS THAN FOR OTHERS?,A Coles,,,0,2012
DEBATE# 2: RESOLVED THAT MS TREATMENTS VARY IN EFFECTIVENESS BASED ON WHETHER THE IMMUNE SYSTEM IS TH1 OR TH17 POLARIZED: NEGATIVE ARGUMENT,A Coles,,,0,2012
Past and Present of Disease-Modifying Treatments in Multiple Sclerosis,M Eraksoy,"NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY 48, 46-55",,0,2011
Preventing the immunogenicity of biological therapies,"J Somerfield, H Waldmann, DAS Compston, G Hale, AJ Coles",MULTIPLE SCLEROSIS JOURNAL 17,,0,2011
Long-term disability improvement after alemtuzumab treatment is maintained in an open-label cohort,"O Tuohy, K May, J Jones, I Bjornson, A Compston, AJ Coles","MULTIPLE SCLEROSIS JOURNAL 17, S443-S443",,0,2011
Alemtuzumab for multiple sclerosis in patients who have relapsed on therapy: CARE-MS II Baseline Demographics and Disease Characteristics,"E Fox, DL Arnold, J Cohen, AJ Coles, C Confavreux, HP Hartung, ...","MULTIPLE SCLEROSIS JOURNAL 17, S417-S417",,0,2011
Immune Responses to Vaccination in Multiple Sclerosis Patients Post-alemtuzumab Treatment (CAM-VAC study),"CL McCarthy, O Tuohy, JL Jones, SJ Thompson, DAS Compston, ...","MULTIPLE SCLEROSIS JOURNAL 17, S346-S347",,0,2011
Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis,"AJ Coles, JL Jones, A Compston","US Patent App. 13/123,188",,0,2011
The ethical issues of trials of neural grafting in patients with neurodegenerative,"RA Barker, A Coles","Oxford Handbook of Neuroethics, 455",,0,2011
An evolving case of headaches and strokes,"AJ Shah, DP Breen, D Thomas, J Cross, A Coles, P Molyneux","Practical neurology 11 (2), 113-117",,0,2011
XYZ,"AJ Larner, AJ Coles, NJ Scolding, RA Barker","AZ of Neurological Practice, 806-810",,0,2011
Erratum: AZ of Neurological Practice,"AJ Larner, AJ Coles, NJ Scolding, RA Barker","AZ of Neurological Practice, E1-E1",,0,2011
"MULTIPLE CRANIAL NEUROPATHIES, A RARE COMPLICATION OF SYSTEMIC SCLEROSIS","A Oomatia, A Young, FC Hall, DR Jayne, AJ Coles, N Shenker, MS Zandi, ...","CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 29 (1), 191-191",,0,2011
Monoclonal antibody treatment of multiple sclerosis,A Coles,Immunology 131,,0,2010
Delayed thymic reconstitution following alemtuzumab (Campath-1H) treatment of multiple sclerosis—implications for secondary autoimmunity: 355,"J Jones, A Coles",Immunology 131,,0,2010
PATU7 Autoimmune diseases after alemtuzumab treatment for multiple sclerosis: findings from a multicentre UK cohort,"MD Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ...","Journal of Neurology, Neurosurgery & Psychiatry 81 (11), e26-e26",,0,2010
A multisystem selenoprotein disorder with a thyroid signature,"N Schoenmakers, E Schoenmakers, M Agostini, C Mitchell, L Papp, ...",Society for Endocrinology BES 2010 21,,0,2010
Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab,"R Muller, J Jones, C Dahler, A Compston, C Mobs, A Coles, E Wenzel, ...","CLINICAL IMMUNOLOGY-SAN DIEGO-ACADEMIC PRESS- 135 (1), S103-S103",,0,2010
INFORMED CONSENT-WHO IS IN THE KNOW?,"AL Cox, AJ Coles",JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 80 (11),,0,2009
Related disorders,M Heger,"Scientific American Mind 20 (6), 7",,0,2009
Alemtuzumab,A Coles,European Journal of Neurology 16,,0,2009
166 Isolated cerebral aspergilloma in a young immunocompetent patient,"A Chancellor, M Hutchinson, A Coles, N Mistry, J Wass, MR Turner, ...",,,0,2009
SERUM AUTOANTIBODIES TO GLUTAMIC ACID DECARBOXYLASE ARE ASSOCIATED WITH REDUCED CORTICAL GABA LEVELS IN PATIENTS WITH EPILEPSY,"CJ Stagg, B Lang, JG Hest, A Cavey, H Johansen-Berg, A Coles, Y Hart, ...",JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 80 (4),,0,2009
Regulatory T cells are persistently enriched in the peripheral blood of head-injury patients,"EJ Galtrey, AL Cox, DA Chatfield, AJ Coles, DK Menon","Critical Care 13 (1), P82",,0,2009
多发性硬化症,尚利,"世界临床医学: 柳叶刀中文版, 515-531",,0,2009
Serum IL-21 predicts the development of autoimmunity in humans following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H),"J Jones, A Cox, C Phuah, S Thompson, J Shawcross, D Compston, ...",Immunology 125,,0,2008
Article de périodique (Journal article),"L Collès, G Bouillon","PORTA LINGUARUM 10, 45-55",,0,2008
Unpaired oligoclonal bands persist in the cerebrospinal fluid of patients with multiple sclerosis following treatment with alemtuzumab,"J Somerfield, A Green, G Keir, E Thompson, G Giovannoni, A Coles","NEUROLOGY 70 (11), A376-A376",,0,2008
"Alastair Compston, Alasdair Coles",A Coles,"Lancet 372, 1502-17",,0,2008
Natalizumab and PML.,"TM Laufer, GF Wu, AJ Coles, A Khoruts, JM Fraser, JL Jones, C King, ...","Journal of Clinical Investigation 359, 1786-1801",,0,2008
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.,"B Elahi, A Compston, A Coles, C Confavreux, S Vukusic, L Durelli, ...","International Journal of Pharmacology 7 (4), 1502-1517",,0,2008
"Subject Index Vol. 5, No. 1, 2008","JL Jones, AJ Coles, E Taoufik, V Tseveleki, M Euagelidou, M Emmanouil, ...","Neurodegenerative Diseases 5 (1), 54-54",,0,2008
"Author Index Vol. 5, No. 1, 2008","JL Jones, AJ Coles, E Taoufik, V Tseveleki, M Euagelidou, M Emmanouil, ...","Neurodegenerative Diseases 5 (1), 53-53",,0,2008
Therapeutic Antibodies in Multiple Sclerosis,"B Becher, N Goebels",S. Karger,,0,2008
014 NEUROPROTECTIVE AUTOIMMUNITY FOLLOWING CAMPATH-1H TREATMENT OF MULTIPLE SCLEROSIS,"JL Jones, JM Anderson, DAS Compston, AJ Coles","Journal Of Neurology, Neurosurgery, & Psychiatry 78 (9)",,0,2007
Change in lymphocyte gene expression induced by Campath-1H treatment of multiple sclerosis,"JA Somerfield, JL Jones, VH Robertson, DAS Compston, AJ Coles","JOURNAL OF NEUROLOGY 254, 35-35",,0,2007
"Homeostatic release of IL-15 to drive lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis generates"" regulatory"" T cells.","VH Robertson, AL Cox, SAJ Thompson, DAS Compston, AJ Coles","NEUROLOGY 68 (12), A399-A399",,0,2007
Abnormal caspase-3 expression underlies defective T-cell apoptosis in multiple sclerosis: Defect reversed by alemtuzumab treatment.,"JL Jones, SJ Thompson, VH Robertson, D Alastair, S Compston, AJ Coles","NEUROLOGY 68 (12), A19-A19",,0,2007
Neurotrophin secretion after lymphodepletion with Campath-1H in multiple sclerosis,"JL Jones, S Thompson, BS Simpson, AL Cox, DAS Compston, AJ Coles","JOURNAL OF NEUROIMMUNOLOGY 178, 211-212",,0,2006
Increased apoptotic elimination of activated T-cells following Campath-1H as a treatment of multiple sclerosis,"JL Jones, SAJ Thompson, J Deans, VH Robertson, DAS Compston, ...","JOURNAL OF NEUROIMMUNOLOGY 178, 54-55",,0,2006
B cell homeostasis and the role of B cell activating factor in patients with Multiple Sclerosis treated with Campath-1H,"SAJ Thompson, JL Jones, AL Cox, BLC Wright, DAS Compston, AJ Coles","JOURNAL OF NEUROIMMUNOLOGY 178, 212-212",,0,2006
The double edged sword of treating autoimmunity: Insights from therapeutic lymphocyte depletion in the treatment of multiple sclerosis,"AL Cox, B Wright, SAJ Thompson, JL Jones, VH Robertson, ...","JOURNAL OF NEUROIMMUNOLOGY 178, 212-213",,0,2006
Lymphocyte homeostasis and regulatory cells in multiple sclerosis,"VH Robertson, AL Cox, SAJ Thompson, JL Jones, DAS Compston, ...","JOURNAL OF NEUROIMMUNOLOGY 178, 211-211",,0,2006
The AZ of Neurological Practice: a Guide to Clinical Neurology,"RA Barker, N Scolding, D Rowe, AJ Larner","AMERICAN JOURNAL OF NEURORADIOLOGY 27 (1), 236",,0,2006
048 AN INVESTIGATION INTO PROTECTIVE AUTOIMMUNITY AFTER TRAUMATIC HEAD INJURY,"AL Cox, J Nortje, PG Bradley, DA Chatfield, DK Menon, AJ Coles","Journal Of Neurology, Neurosurgery, & Psychiatry 77 (1), 134-135",,0,2006
Sa. 23. The Role of IL-7 in the Induction of Regulatory T-Cells After Campath-1h,"V Robertson, A Cox, SA Thompson, J Jones, DA Compston, A Coles","Clinical Immunology, S113",,0,2006
Sa. 14. Increased Apoptotic Elimination of T-Cells After Immunotherapy for Multiple Sclerosis,"J Jones, S Thompson, V Robertson, DA Compston, A Coles","Clinical Immunology, S109-S110",,0,2006
Treatment resistant jerky stiff person syndrome,"TP Harrower, R Barker, J Baron, A Coles","MOVEMENT DISORDERS 21, S432-S432",,0,2006
074 A SURVEY OF AUTOIMMUNITY AFTER THERAPEUTIC LYMPHOCYTE DEPLETION IN THE TREATMENT OF MULTIPLE SCLEROSIS,"AL Cox, JL Jones, SJ Thompson, J Deans, DAS Compston, AJ Coles","Journal Of Neurology, Neurosurgery, & Psychiatry 77 (1)",,0,2006
Increased apoptotic elimination of activated T-cells after Campath-1H treatment of multiple sclerosis,"JL Jones, SAJ Thompson, VH Robertson, DAS Compston, AJ Coles","IMMUNOLOGY 116, 41-41",,0,2005
B lymphocyte homeostasis in multiple sclerosis patients treated with CAMPATH-1H,"SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles","IMMUNOLOGY 116, 42-42",,0,2005
The homeostatic response to lymphocyte depletion in multiple sclerosis,"A Cox, S Thompson, J Jones, D Compston, A Coles",Immunology-Supplement 113,,0,2004
"NEURAL STEM CELLS FOR BRAIN AND SPINAL CORD REPAIR Tanya Zigova, Evan Snyder and Paul Sanberg, editors. 2002. Totowa (NJ) Humana Press Price 149.50.ISBN1588290034STILLLIVES …","A Coles, R Barker","Brain 127 (12), 2779-2782",,0,2004
Defining human T lymphocyte subsets using putative markers derived from mouse sage libraries,"SAJ Thompson, S Cobbold, H Waldmann, A Coles",JOURNAL OF NEUROIMMUNOLOGY 154 (1-2),,0,2004
Exogenous dehydroepiandrosterone replacement in humans induces regulatory T cells,"SAJ Thompson, S Curran, A Cox, K Chatterjee, A Coles","JOURNAL OF NEUROIMMUNOLOGY 154 (1-2), 132-132",,0,2004
Lymphocyte homeostasis in multiple sclerosis,"AL Cox, SAJ Thompson, JL Jones, DAS Compston, AJ Coles","JOURNAL OF NEUROIMMUNOLOGY 154 (1-2), 225-225",,0,2004
"Inflammation, Demyelination, and Axonal Degeneration","AJ COLES, MG WING, P MOLYNEUX, A PAOLILLO, CM DAVIE, G HALE, ...","Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis, 15",,0,2004
"Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment","AJ Coles, MG Wing, P Molyneux, A Paolillo, CM Davie, G Hale, D Miller, ...","Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis, 15-25",,0,2004
Pathophysiology of disability in multiple sclerosis,AJ Coles,"Neurol Sci 25, S349-S351",,0,2004
Vasculitis complicating cerebral amyloid angiopathy: A cause of reversible dementia,"KAC Harkness, A Coles, U Pohl, J Xuereb, JC Baron, G Lennox","JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 74 (8), 1178-1178",,0,2003
Campath-1H in the treatment of patients with worsening multiple sclerosis,"AL Cox, E Le Page, AJ Coles, D Miller, G Hale, H Waldman, ...","BRITISH MED JOURNAL PUBL GROUP 74 (3), 407-407",,0,2003
Channelopathies of the Nervous System,A Coles,"Brain 125 (12), 2788-2789",,0,2002
More MS news articles for May 2002,A Coles,"Lancet 359, 1221-31",,0,2002
"Multiple Sclerosis: Ethics, Outcome Variables and Clinical Scales","AJ Coles, DAS Compston","Clinical Trials in Neurology, 359-370",,0,2001
A Short History of Neurology,A Coles,"Journal of neurology, neurosurgery, and psychiatry 69 (2), 283",,0,2000
Multiple Sclerosis in Clinical Practice,A Coles,"Journal of neurology, neurosurgery, and psychiatry 69 (1), 139",,0,2000
Immunological and Infectious Diseases of the Peripheral Nerves.,A Coles,"Journal of neurology, neurosurgery, and psychiatry 66 (3), 412",,0,1999
Pulsed monoclonal antibody treatment of multiple sclerosis suppresses new lesion formation but not the progression of disability or cerebral atrophy,"AJ COLES, A PAOLILI, P MOLYNEUX, MG WING, G HALE, ...","Journal of Neurology, Neurosurgery, and Psychiatry 65 (3)",,0,1998
Pocket Companion to Neurology in Clinical Practice,A Coles,"Journal of neurology, neurosurgery, and psychiatry 63 (2), 274",,0,1997
Introduction to Clinical Neurology,A Coles,"Journal of neurology, neurosurgery, and psychiatry 60 (6), 705",,0,1996
Manual of Neurologic Therapeutics,A Coles,"Journal of neurology, neurosurgery, and psychiatry 60 (2), 249",,0,1996
Basic Human Neuroanatomy. An Introductory Atlas,A Coles,"Journal of neurology, neurosurgery, and psychiatry 60 (2), 249",,0,1996
Transient neurological deterioration associated with cytokine release induced by lymphocyte depletion immunotherapy in multiple sclerosis,"AJ Coles, T Moreau, MG Wing, DAS Compston","MULTIPLE SCLEROSIS 2, 4.6-4.6",,0,1996
"Temporal Lobe Epilepsy, Dostoyevsky and Irrational Significance",A Coles,,,0,0
The Discipline of Neurology,A Coles,,,0,0
Diagnosis of CJD,"J Ironside, A Lowman, M Manford, S Hamdy, B Ganglia, A Coles, J Cross, ...",,,0,0
MRI lesion volume measurement in multiple,"ML Gawne-Cain, JI O'Riordan, A Coles, B Newell, AJ Thompson, ...",,,0,0
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features,"A Le, N Pariani, M Willis, I Muller, S Healy, T Nasser, A Mcgowan, ...",,,0,0
Plasma cell depletion with bortezomib in the treatment of refractory NMDAR-antibody encephalitis. Rational developments in neuroimmunological treatment.,"S Keddie, SJ Crisp, J Blackaby, A Cox, A Coles, M Hart, AJ Church, ...",,,0,0
Antibody-mediated encephalitis: a treatable cause of,"BR Lennox, AJ Coles, A Vincent",,,0,0
FDA Wants More Data Before Approving Alemtuzumab for MS,"JA Cohen, AJ Coles, DL Arnold",,,0,0
A5 Editorial Board A7 Highlights of this issue,"J Read, RP Bentall, MP Weller, BR Lennox, AJ Coles, A Vincent, ...",,,0,0
"Our thanks to all those who have helped with this issue. Listed below are authors, referees and others who have kindly given their time, effort and expertise; their generosity …","A Ahmed, D Alexopoulos, F Alfonso, M Amaki, S Banerjee, M Basalus, ...",,,0,0
Neurology and Religion,"F Watts, A Coles",,,0,0
Emerging oral therapies to treat MS,A Coles,,,0,0
Temporal lobe epilepsy and Dostoyevsky seizures: Neuropathology and Spirituality,A Coles,,,0,0
Religion and Neurology,"A Coles, F Watts",,,0,0
"Our thanks to all those who have helped with this issue. Listed below are authors, referees and others who have kindly given their time, effort and expertise; their generosity …","M Abrao, M Auer, L Bahamondes, M Bahamondes, R Bekkers, ...",,,0,0
1. 1916: The pathological anatomy of the lesion in multiple sclerosis,"A Coles, A Compston",,,0,0
A Novel Presentation of Multiple Cranial Neuropathies in Systemic Sclerosis,"A Oomatia, AMH Young, S Rae, DRW Jayne, AJ Coles, FC Hall, ...",,,0,0
The Board of the European Charcot Foundation thanks the Editorial Experts who contributed to this issue by reviewing the manuscripts,"MP Amato, F Barkhof, T Berger, A Coles, C Confavreux, J de Keyser, ...",,,0,0
The story of Campath,A Coles,,,0,0
